Cytotoxic Effects of Temozolomide and Radiation are Additive- and Schedule-Dependent

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 5, 2009, Pages 1511-1519

  Chalmers, Anthony J ^a,b   Ruff, Elliot M ^c   Martindale, Christine ^d   Lovegrove, Nadia ^b   Short, Susan C ^d  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemoradiation; G2 M checkpoint; Glioblastoma multiforme; Radiation therapy; Temozolomide

Indexed keywords

ATAXIA-TELANGIECTASIA MUTATED; CELL CYCLE; CELL-CYCLE ARREST; CHEMORADIATION; CLONOGENIC SURVIVAL; COMBINATION THERAPY; CYTOPROTECTIVE EFFECTS; CYTOTOXIC EFFECTS; DEVELOPING STRATEGY; DNA BREAKS; DNA DAMAGES; DNA REPAIR; DNA-METHYLTRANSFERASE; GLIOBLASTOMA MULTIFORME; GLIOMA CELL LINES; KINASE INHIBITORS; RADIATION SENSITIVITY; RADIATION THERAPY; RADIATION-INDUCED; RADIO-SENSITIZATION; TEMOZOLOMIDE;

ASYNCHRONOUS TRANSFER MODE; AUTOMATIC TELLER MACHINES; CELL CULTURE; CHEMOTHERAPY; CYTOTOXICITY; DNA; GENES; INTERNET PROTOCOLS; NUCLEIC ACIDS; PHOSPHORYLATION; RADIOTHERAPY; SIGNALING;

RADIATION EFFECTS;

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, ALKYLATING; CAFFEINE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DACARBAZINE; DNA REPAIR; DNA-BINDING PROTEINS; DRUG ADMINISTRATION SCHEDULE; G2 PHASE; GLIOBLASTOMA; HUMANS; MORPHOLINES; NEOPLASM PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PYRONES; RADIATION TOLERANCE; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 71649087715     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1703     Document Type: Article

References (22)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Marchesi F., Turriziani M., Tortorelli G., et al. Triazene compounds: Mechanism of action and related DNA repair systems. Pharmacol Res 56 (2007) 275-287
3. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
4. van Rijn J., Heimans J.J., van den Berg J., et al. Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47 (2000) 779-784
5. Chakravarti A., Erkkinen M.G., Nestler U., et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 12 (2006) 4738-4746
6. Caporali S., Falcinelli S., Starace G., et al. DNA damage induced by temozolomide signals to both ATM and ATR: Role of the mismatch repair system. Mol Pharmacol 66 (2004) 478-491
7. Hirose Y., Berger M.S., and Pieper R.O. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61 (2001) 5843-5849
8. Hickson I., Zhao Y., Richardson C.J., et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64 (2004) 9152-9159
9. Short S.C., Martindale C., Bourne S., et al. DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro Oncol 9 (2007) 404-411
10. Kanzawa T., Bedwell J., Kondo Y., et al. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99 (2003) 1047-1052
11. Chan C.L., Wu Z., Eastman A., et al. Irradiation-induced expression of O6-methylguanine-DNA methyltransferase in mammalian cells. Cancer Res 52 (1992) 1804-1809
12. Grombacher T., Mitra S., and Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 17 (1996) 2329-2336
13. Kuhne M., Riballo E., Rief N., et al. A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res 64 (2004) 500-508
14. Wedge S.R., Porteous J.K., Glaser M.G., et al. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8 (1997) 92-97
15. van Nifterik K.A., van den Berg J., Stalpers L.J., et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69 (2007) 1246-1253
16. Combs S.E., Schulz-Ertner D., Roth W., et al. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 68 (2007) 873-882
17. Kil W.J., Cerna D., Burgan W.E., et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14 (2008) 931-938
18. Roos W.P., Batista L.F., Naumann S.C., et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26 (2007) 186-197
19. Stojic L., Cejka P., and Jiricny J. High doses of SN1 type methylating agents activate DNA damage signaling cascades that are largely independent of mismatch repair. Cell Cycle 4 (2005) 473-477
20. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3 (2003) 155-168
21. Caporali S., Levati L., Starace G., et al. AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol 74 (2008) 173-183
22. Lupardus P.J., Byun T., Yee M.C., et al. A requirement for replication in activation of the ATR-dependent DNA damage checkpoint. Genes Dev 16 (2002) 2327-2332